Daily Stock Analysis, EGRX, Eagle Pharmaceuticals Inc, priceseries

Eagle Pharmaceuticals Inc. Daily Stock Analysis
Stock Information
Open
53.49
Close
54.20
High
55.66
Low
52.75
Previous Close
53.89
Daily Price Gain
0.31
YTD High
59.58
YTD High Date
May 8, 2019
YTD Low
38.38
YTD Low Date
Feb 11, 2019
YTD Price Change
13.50
YTD Gain
33.17%
52 Week High
85.66
52 Week High Date
Jul 20, 2018
52 Week Low
36.03
52 Week Low Date
Dec 24, 2018
52 Week Price Change
-25.46
52 Week Gain
-31.96%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Jun 14. 2017
73.04
Jun 29. 2017
79.17
11 Trading Days
8.40%
Link
LONG
Jul 5. 2018
76.53
Jul 24. 2018
81.56
13 Trading Days
6.57%
Link
LONG
Feb 14. 2019
40.53
Mar 7. 2019
46.89
14 Trading Days
15.69%
Link
LONG
May 3. 2019
51.12
May 15. 2019
55.12
8 Trading Days
7.82%
Link
Company Information
Stock Symbol
EGRX
Exchange
NasdaqGM
Company URL
http://www.eagleus.com
Company Phone
201-326-5300
CEO
Scott L. Tarriff
Headquarters
New Jersey
Business Address
50 TICE BOULEVARD, SUITE 315, WOODCLIFF LAKE, NJ 07677
Sector
Equity
Industry Category
Drugs
Industry Group
Drugs - Generic
CIK
0000827871
About

Eagle Pharmaceuticals, Inc. is a pharmaceutical company engages in the provision of injectable products. Its activities include development and commercialization of pharmaceutical products for the treatment of areas such as critical care, orphan diseases, and oncology. The company was founded by Scott L. Tarriff on January 2, 2007 and is headquartered in Woodcliff Lake, NJ.

Description

Eagle Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company offers argatroban for heparin-induced thrombocytopenia; Ryanodex for malignant hyperthermia; non-alcohol docetaxel injection, a chemotherapeutic agent for breast, non-small cell lung, prostate, head, and neck cancers/gastric adenocarcinoma; and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates includes include EP-4104, a dantrolene sodium for exertional heat stroke; EGL-4104-C-1702, dantrolene sodium for drug induced hyperthermia; EP-5101 (pemetrexed) for lung cancer and mesothelioma; and EGL-5385-C-1701 (fulvestrant) for breast cancer. Eagle Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Woodcliff Lake, New Jersey.